Trial Profile

A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobitolimod (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms CONDUCT
Sponsors Flerie; InDex Pharmaceuticals

Most Recent Events

23 Aug 2021 According to an InDex Pharmaceuticals media release, the wo new employees have been appointed in the clinical development organisation in preparation of the start of this trial.
21 Nov 2020 This trial is Completed in Italy, according to European Clinical Trials Database record.
28 Oct 2020 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com